Cathy Cluver Tygerberg Hospital, Stellenbosch University Cape Town, South Africa
Dr. Cathy Cluver is an obstetrician-gynaecologist and maternal-fetal medicine subspecialist who is completing her PhD on the management and treatment of preterm preeclampsia. She is based at Tygerberg Hospital and Stellenbosch University in Cape Town, South Africa, where she leads the Preeclampsia Research Unit. The Preeclampsia Research Unit has two main arms—Therapeutic trials for novel treatments for preterm preeclampsia and the PReeclampsia Obstetric adVerse Events (PROVE) Biobank.
PROVE (Preeclampsia Obstetric Adverse Events) Biobank Together with Dr. Berman, Dr. Cluver runs and manages the PROVE biobank with the aim to gain knowledge regarding organ failure in preeclampsia and primarily cerebral and cardiovascular complications. This will be achieved through the establishment of a bio- and databank at Tygerberg Hospital, Stellenbosch University, where longitudinal blood samples, placenta samples, cerebrospinal fluid and cord blood are collected together with a databank consisting of predictors and outcomes in agreement with the COLLECT database and in addition investigations such as MRI brain, estimation of cerebral blood flow through Doppler measurements, MRI heart and echocardiography for women with preeclampsia and organ complications and healthy pregnant controls. The results of the project will hopefully yield a possibility to customize treatment to specific organ involvement, reach new discoveries regarding future drug targets and facilitate surveillance and treatment of women at high risk of mortality and morbidity due to preeclampsia.
Therapeutic trials for novel treatments for preterm preeclampsia: Together with international researchers, including Professors Sue Walker and Stephen Tong, Dr. Cluver has recently completed her first double blind randomised control trial of 40mg esomeprazole to treat preterm preeclampsia: the Preeclampsia Intervention with Esomeprazole (PIE) trial. 120 women with preterm preeclampsia were recruited in 14 months, plasma and placental samples were collected, analysed and have been stored for further research and detailed pharmacokinetic studies were performed. The team is currently recruiting for a second double blind randomised control trial where 3gm of daily metformin versus placebo is being assessed as a therapeutic for preterm preeclampsia (PI2 trial).
GO-PROVE – Gothenburg Preeclampsia Obstetric Adverse Events Drs. Bergman and Cluver, together with a team of researchers from Gothenburg University including midwifes, anesthesiologist, radiologists and obstetricians, are setting up a biobank and database with the same predictors and some of the outcomes from PROVE. The project aims to discover new objective biomarkers as predictors for organ impairment in a Swedish setting on short- and long-term and to validate findings from PROVE.
|